|
1
|
Shay JW and Wright WE: Hallmarks of
telomeres in ageing research. J Pathol. 211:114–123. 2007.
View Article : Google Scholar
|
|
2
|
Pańczyszyn A, Boniewska-Bernacka E and Goc
A: The role of telomeres and telomerase in the senescence of
postmitotic cells. DNA Repair (Amst). 95:1029562020. View Article : Google Scholar
|
|
3
|
Smith EM, Pendlebury DF and Nandakumar J:
Structural biology of telomeres and telomerase. Cell Mol Life Sci.
77:61–79. 2020. View Article : Google Scholar
|
|
4
|
Ameh OI, Okpechi IG, Dandara C and Kengne
AP: Association between telomere length, chronic kidney disease,
and renal traits: A systematic review. OMICS. 21:143–155. 2017.
View Article : Google Scholar
|
|
5
|
Bolignano D, Mattace-Raso F, Sijbrands EJ
and Zoccali C: The aging kidney revisited: A systematic review.
Ageing Res Rev. 14:65–80. 2014. View Article : Google Scholar
|
|
6
|
Sitaram RT, Cairney CJ, Grabowski P, Keith
WN, Hallberg B, Ljungberg B and Roos G: The PTEN regulator DJ-1 is
associated with hTERT expression in clear cell renal cell
carcinoma. Int J Cancer. 125:783–790. 2009. View Article : Google Scholar
|
|
7
|
Svenson U, Gronlund E, Soderstrom I,
Sitaram RT, Ljungberg B and Roos G: Telomere length in relation to
immunological parameters in patients with renal cell carcinoma.
PLoS One. 8:e555432013. View Article : Google Scholar
|
|
8
|
Melk A, Schmidt BM, Takeuchi O, Sawitzki
B, Rayner DC and Halloran PF: Expression of p16INK4a and other cell
cycle regulator and senescence associated genes in aging human
kidney. Kidney Int. 65:510–520. 2004. View Article : Google Scholar
|
|
9
|
de Lange T: A loopy view of telomere
evolution. Front Genet. 6:3212015. View Article : Google Scholar
|
|
10
|
Wood AM, Laster K, Rice EL and Kosak ST: A
beginning of the end: New insights into the functional organization
of telomeres. Nucleus. 6:172–178. 2015. View Article : Google Scholar
|
|
11
|
de Lange T: Protection of mammalian
telomeres. Oncogene. 21:532–540. 2002. View Article : Google Scholar
|
|
12
|
Nagpal N and Agarwal S: Telomerase RNA
processing: Implications for human health and disease. Stem Cells.
2020.(Epub ahead of print). View Article : Google Scholar
|
|
13
|
Serakinci N, Graakjaer J and Kolvraa S:
Telomere stability and telomerase in mesenchymal stem cells.
Biochimie. 90:33–40. 2008. View Article : Google Scholar
|
|
14
|
Blagoev KB: Cell Proliferation in the
presence of telomerase. PLoS One. 4:e26222009. View Article : Google Scholar
|
|
15
|
Cong YS, Wright WE and Shay JW: Human
telomerase and its regulation. Microbiol Mol Biol Rev. 66:407–425,
table of contents. 2002. View Article : Google Scholar
|
|
16
|
Buseman CM, Wright WE and Shay JW: Is
telomerase a viable target in cancer? Mutat Res. 730:90–97. 2012.
View Article : Google Scholar
|
|
17
|
Melk A, Kittikowit W, Sandhu I, Halloran
KM, Grimm P, Schmidt BMW and Halloran PF: Cell senescence in rat
kidneys in vivo increases with growth and age despite lack of
telomere shortening. Kidney Int. 63:2134–2143. 2003. View Article : Google Scholar
|
|
18
|
Li Y and Lerman LO: Cellular senescence: A
new player in kidney injury. Hypertension. 76:1069–1075. 2020.
View Article : Google Scholar
|
|
19
|
Kato S, Shiels PG, McGuinness D, Lindholm
B, Stenvinkel P, Nordfors L, Qureshi AR, Yuzawa Y, Matsuo S and
Maruyama S: Telomere attrition and elongation after chronic
dialysis initiation in patients with end-stage renal disease. Blood
Purif. 41:25–33. 2016. View Article : Google Scholar
|
|
20
|
Perico N, Remuzzi G and Benigni A: Aging
and the kidney. Curr Opin Nephrol Hypertens. 20:312–317. 2011.
View Article : Google Scholar
|
|
21
|
Abdel-Rahman EM and Okusa MD: Effects of
aging on renal function and regenerative capacity. Nephron Clin
Pract. 127:15–20. 2014. View Article : Google Scholar
|
|
22
|
Wills LP and Schnellmann RG: Telomeres and
telomerase in renal health. J Am Soc Nephrol. 22:39–41. 2011.
View Article : Google Scholar
|
|
23
|
Blasco MA, Lee HW, Hande MP, Samper E,
Lansdorp PM, DePinho RA and Greider CW: Telomere shortening and
tumor formation by mouse cells lacking telomerase RNA. Cell.
91:25–34. 1997. View Article : Google Scholar
|
|
24
|
Wright WE and Shay JW: Telomere dynamics
in cancer progression and prevention: Fundamental differences in
human and mouse telomere biology. Nat Med. 6:849–851. 2000.
View Article : Google Scholar
|
|
25
|
Kloda K, Domanski L, Kwiatkowska E,
Borowiecka E, Safranow K, Drozd A, Ciechanowicz A,
Maciejewska-Karłowska A, Sawczuk M, Pawlik A and Ciechanowski K:
hTERT, BICD1 and chromosome 18 polymorphisms associated with
telomere length affect kidney allograft function after
transplantation. Kidney Blood Press Res. 40:111–120. 2015.
View Article : Google Scholar
|
|
26
|
O'Hare AM, Bertenthal D, Walter LC, Garg
AX, Covinsky K, Kaufman JS, Rodriguez RA and Allon M: When to refer
patients with chronic kidney disease for vascular access surgery:
Should age be a consideration? Kidney Int. 71:555–561. 2007.
View Article : Google Scholar
|
|
27
|
Verzola D, Gandolfo MT, Gaetani G,
Ferraris A, Mangerini R, Ferrario F, Villaggio B, Gianiorio F,
Tosetti F, Weiss U, et al: Accelerated senescence in the kidneys of
patients with type 2 diabetic nephropathy. Am J Physiol Renal
Physiol. 295:F1563–F1573. 2008. View Article : Google Scholar
|
|
28
|
Lindeman RD, Tobin J and Shock NW:
Longitudinal studies on the rate of decline in renal function with
age. J Am Geriatr Soc. 33:278–285. 1985. View Article : Google Scholar
|
|
29
|
Chow WH, Dong LM and Devesa SS:
Epidemiology and risk factors for kidney cancer. Nat Rev Urol.
7:245–257. 2010. View Article : Google Scholar
|
|
30
|
Klatte T, Rossi SH and Stewart GD:
Prognostic factors and prognostic models for renal cell carcinoma:
A literature review. World J Urol. 36:1943–1952. 2018. View Article : Google Scholar
|
|
31
|
Morais M, Dias F, Teixeira AL and Medeiros
R: Telomere length in renal cell carcinoma: The Jekyll and Hyde
biomarker of ageing of the kidney. Cancer Manag Res. 12:1669–1679.
2020. View Article : Google Scholar
|
|
32
|
Pal D, Sharma U, Singh SK, Kakkar N and
Prasad R: Inhibition of hTERT expression by MAP kinase inhibitor
induces cell death in renal cell carcinoma. Urol Oncol. 35:401–408.
2017. View Article : Google Scholar
|
|
33
|
Wu X, Amos CI, Zhu Y, Zhao H, Grossman BH,
Shay JW, Luo S, Hong WK and Spitz MR: Telomere dysfunction: A
potential cancer predisposition factor. J Natl Cancer Inst.
95:1211–1218. 2003. View Article : Google Scholar
|
|
34
|
Mehle C, Ljungberg B and Roos G: Telomere
shortening in renal cell carcinoma. Cancer Res. 54:236–241.
1994.
|
|
35
|
Gisselsson D, Gorunova L, Hoglund M,
Mandahl N and Elfving P: Telomere shortening and mitotic
dysfunction generate cytogenetic heterogeneity in a subgroup of
renal cell carcinomas. Br J Cancer. 91:327–332. 2004. View Article : Google Scholar
|
|
36
|
Carrozza F, Santoni M, Piva F, Cheng L,
Lopez-Beltran A, Scarpelli M, Montironi R, Battelli N and Tamberi
S: Emerging immunotherapeutic strategies targeting telomerases in
genitourinary tumors. Crit Rev Oncol Hematol. 131:1–6. 2018.
View Article : Google Scholar
|
|
37
|
Svenson U, Ljungberg B and Roos G:
Telomere length in peripheral blood predicts survival in clear cell
renal cell carcinoma. Cancer Res. 69:2896–2901. 2009. View Article : Google Scholar
|
|
38
|
Demanelis K, Jasmine F, Chen LS, Chernoff
M, Tong L, Delgado D, Zhang C, Shinkle J, Sabarinathan M, Lin H, et
al: Determinants of telomere length across human tissues. Science.
369:eaaz68762020. View Article : Google Scholar
|
|
39
|
Aramburu T, Plucinsky S and Skordalakes E:
POT1-TPP1 telomere length regulation and disease. Comput Struct
Biotechnol J. 18:1939–1946. 2020. View Article : Google Scholar
|
|
40
|
Pal D, Singh SK, Kakkar N and Prasad R:
Expression of telomere binding proteins (RAP1 and POT1) in renal
cell carcinoma and their correlation with clinicopathological
parameters. Indian J Clin Biochem. 32:301–305. 2017. View Article : Google Scholar
|
|
41
|
Dahse R, Fiedler W, Junker K, Schlichter
A, Schubert J and Claussen U: Telomerase activity and telomere
lengths: Alterations in renal cell carcinomas. Kidney Int.
56:1289–1290. 1999. View Article : Google Scholar
|
|
42
|
Sugimura K, Yoshida N, Hisatomi H,
Nakatani T and Ikemoto S: Telomerase activity in human renal cell
carcinoma. BJU Int. 83:693–697. 1999. View Article : Google Scholar
|
|
43
|
Tonelli M and Riella MC: Chronic kidney
disease and the aging population. Kidney Int. 85:487–491. 2014.
View Article : Google Scholar
|
|
44
|
Kremers WK, Denic A, Lieske JC, Alexander
MP, Kaushik V, Elsherbiny HE, Chakkera HA, Poggio ED and Rule AD:
Distinguishing age-related from disease-related glomerulosclerosis
on kidney biopsy: The aging kidney anatomy study. Nephrol Dial
Transplant. 30:2034–2039. 2015. View Article : Google Scholar
|
|
45
|
Nitta K, Okada K, Yanai M and Takahashi S:
Aging and chronic kidney disease. Kidney Blood Press Res.
38:109–120. 2013. View Article : Google Scholar
|
|
46
|
Cañadas-Garre M, Anderson K, Cappa R,
Skelly R, Smyth LJ, McKnight AJ and Maxwell AP: Genetic
susceptibility to chronic kidney disease-some more pieces for the
heritability puzzle. Front Genet. 10:4532019. View Article : Google Scholar
|
|
47
|
Tonelli M and Riella M: Chronic kidney
disease and the aging population. J Cross Cult Gerontol.
29:231–237. 2014. View Article : Google Scholar
|
|
48
|
Mazidi M, Rezaie P, Covic A, Malyszko J,
Rysz J, Kengne AP and Banach M: Telomere attrition, kidney
function, and prevalent chronic kidney disease in the United
States. Oncotarget. 8:80175–80181. 2017. View Article : Google Scholar
|
|
49
|
Kidir V, Aynali A, Altuntas A, Inal S,
Aridogan B and Sezer MT: Telomerase activity in patients with stage
2–5D chronic kidney disease. Nefrologia. 37:592–597. 2017.(In
English and Spanish). View Article : Google Scholar
|
|
50
|
Tsirpanlis G, Chatzipanagiotou S, Boufidou
F, Kordinas V, Alevyzaki F, Zoga M, Kyritsis I, Stamatelou K,
Triantafyllis G and Nicolaou C: Telomerase activity is decreased in
peripheral blood mononuclear cells of hemodialysis patients. Am J
Nephrol. 26:91–96. 2006. View Article : Google Scholar
|
|
51
|
Sell DR and Monnier VM: End-stage renal
disease and diabetes catalyze the formation of a pentose-derived
crosslink from aging human collagen. J Clin Invest. 85:380–384.
1990. View Article : Google Scholar
|
|
52
|
Wong LS, van der Harst P, de Boer RA, Codd
V, Huzen J, Samani NJ, Hillege HL, Voors AA, van Gilst WH, Jaarsma
T and van Veldhuisen DJ: Renal dysfunction is associated with
shorter telomere length in heart failure. Clin Res Cardiol.
98:629–634. 2009. View Article : Google Scholar
|
|
53
|
Kooman JP, Dekker MJ, Usvyat LA, Kotanko
P, van der Sande FM, Schalkwijk CG, Shiels PG and Stenvinkel P:
Inflammation and premature aging in advanced chronic kidney
disease. Am J Physiol Renal Physiol. 313:F938–F950. 2017.
View Article : Google Scholar
|
|
54
|
Hu MC, Kuro-o M and Moe OW: Klotho and
chronic kidney disease. Contrib Nephrol. 180:47–63. 2013.
View Article : Google Scholar
|
|
55
|
Vlassara H, Torreggiani M, Post JB, Zheng
F, Uribarri J and Striker GE: Role of oxidants/inflammation in
declining renal function in chronic kidney disease and normal
aging. Kidney Int Suppl. S3-11:2009.
|
|
56
|
Wynn TA and Ramalingam TR: Mechanisms of
fibrosis: Therapeutic translation for fibrotic disease. Nat Med.
18:1028–1040. 2012. View Article : Google Scholar
|
|
57
|
Rockey DC, Bell PD and Hill JA: Fibrosis-a
common pathway to organ injury and failure. N Engl J Med.
372:1138–1149. 2015. View Article : Google Scholar
|
|
58
|
Vaglio A, Salvarani C and Buzio C:
Retroperitoneal fibrosis. Lancet. 367:241–251. 2006. View Article : Google Scholar
|
|
59
|
Sziksz E, Pap D, Lippai R, Béres NJ,
Fekete A, Szabó AJ and Vannay Á: Fibrosis related inflammatory
mediators: Role of the IL-10 cytokine family. Mediators Inflamm.
2015:7646412015. View Article : Google Scholar
|
|
60
|
Nowakowski ACH: Cystic fibrosis kidney
disease: 10 Tips for clinicians. Front Med (Lausanne). 5:2422018.
View Article : Google Scholar
|
|
61
|
Piñeiro-Hermida S, Autilio C, Martínez P,
Bosch F, Pérez-Gil J and Blasco MA: Telomerase treatment prevents
lung profibrotic pathologies associated with physiological aging. J
Cell Biol. 219:e2020021202020. View Article : Google Scholar
|
|
62
|
Sangaralingham SJ, Wang BH, Huang L, Kumfu
S, Ichiki T, Krum H and Burnett JC Jr: Cardiorenal fibrosis and
dysfunction in aging: Imbalance in mediators and regulators of
collagen. Peptides. 76:108–114. 2016. View Article : Google Scholar
|
|
63
|
Cianciolo RE, Benali SL and Aresu L: Aging
in the canine kidney. Vet Pathol. 53:299–308. 2016. View Article : Google Scholar
|
|
64
|
Naesens M: Replicative senescence in
kidney aging, renal disease, and renal transplantation. Discov Med.
11:65–75. 2011.
|
|
65
|
Turner KJ, Vasu V and Griffin DK: Telomere
biology and human phenotype. Cells. 8:732019. View Article : Google Scholar
|
|
66
|
Yang L, Besschetnova TY, Brooks CR, Shah
JV and Bonventre JV: Epithelial cell cycle arrest in G2/M mediates
kidney fibrosis after injury. Nat Med. 16:535–543, 531p following
143. 2010. View Article : Google Scholar
|
|
67
|
Ronco C, Bellomo R and Kellum JA: Acute
kidney injury. Lancet. 394:1949–1964. 2019. View Article : Google Scholar
|
|
68
|
Ishani A, Xue JL, Himmelfarb J, Eggers PW,
Kimmel PL, Molitoris BA and Collins AJ: Acute kidney injury
increases risk of ESRD among elderly. J Am Soc Nephrol. 20:223–228.
2009. View Article : Google Scholar
|
|
69
|
Epel ES, Lin J, Dhabhar FS, Wolkowitz OM,
Puterman E, Karan L and Blackburn EH: Dynamics of telomerase
activity in response to acute psychological stress. Brain Behav
Immun. 24:531–539. 2010. View Article : Google Scholar
|
|
70
|
Kiecolt-Glaser JK and Glaser R:
Psychological stress, telomeres, and telomerase. Brain Behav Immun.
24:529–530. 2010. View Article : Google Scholar
|
|
71
|
Cheng H, Fan X, Lawson WE, Paueksakon P
and Harris RC: Telomerase deficiency delays renal recovery in mice
after ischemia-reperfusion injury by impairing autophagy. Kidney
Int. 88:85–94. 2015. View Article : Google Scholar
|
|
72
|
Zhan M, Brooks C, Liu F, Sun L and Dong Z:
Mitochondrial dynamics: Regulatory mechanisms and emerging role in
renal pathophysiology. Kidney Int. 83:568–581. 2013. View Article : Google Scholar
|
|
73
|
Lane RK, Hilsabeck T and Rea SL: The role
of mitochondrial dysfunction in age-related diseases. Biochim
Biophys Acta. 1847:1387–1400. 2015. View Article : Google Scholar
|
|
74
|
Volarevic V, Djokovic B, Jankovic MG,
Harrell CR, Fellabaum C, Djonov V and Arsenijevic N: Molecular
mechanisms of cisplatin-induced nephrotoxicity: A balance on the
knife edge between renoprotection and tumor toxicity. J Biomed Sci.
26:252019. View Article : Google Scholar
|
|
75
|
Shin YJ, Kim TH, Won AJ, Jung JY, Kwack
SJ, Kacew S, Chung KH, Lee BM and Kim HS: Age-related differences
in kidney injury biomarkers induced by cisplatin. Environ Toxicol
Pharmacol. 37:1028–1039. 2014. View Article : Google Scholar
|
|
76
|
Abdel-Kader K and Palevsky PM: Acute
kidney injury in the elderly. Clin Geriatr Med. 25:331–358. 2009.
View Article : Google Scholar
|
|
77
|
Aubert G and Lansdorp PM: Telomeres and
aging. Physiol Rev. 88:557–579. 2008. View Article : Google Scholar
|
|
78
|
Westhoff JH, Schildhorn C, Jacobi C, Hömme
M, Hartner A, Braun H, Kryzer C, Wang C, von Zglinicki T, Kränzlin
B, et al: Telomere shortening reduces regenerative capacity after
acute kidney injury. J Am Soc Nephrol. 21:327–336. 2010. View Article : Google Scholar
|
|
79
|
Schmitt R and Cantley LG: The impact of
aging on kidney repair. Am J Physiol Renal Physiol.
294:F1265–F1272. 2008. View Article : Google Scholar
|
|
80
|
Andrade L, Rodrigues CE, Gomes SA and
Noronha IL: Acute kidney injury as a condition of renal senescence.
Cell Transplant. 27:739–753. 2018. View Article : Google Scholar
|
|
81
|
Pei Y: Diagnostic approach in autosomal
dominant polycystic kidney disease. Clin J Am Soc Nephrol.
1:1108–1114. 2006. View Article : Google Scholar
|
|
82
|
Mangolini A, de Stephanis L and Aguiari G:
Role of calcium in polycystic kidney disease: From signaling to
pathology. World J Nephrol. 5:76–83. 2016. View Article : Google Scholar
|
|
83
|
Perumareddi P and Trelka DP: Autosomal
dominant polycystic kidney disease. Prim Care. 47:673–689. 2020.
View Article : Google Scholar
|
|
84
|
McConnachie DJ, Stow JL and Mallett AJ:
Ciliopathies and the kidney: A review. Am J Kidney Dis. Oct
8–2020.(Epub ahead of print). View Article : Google Scholar
|
|
85
|
Rangan GK, Tchan MC, Tong A, Wong AT and
Nankivell BJ: Recent advances in autosomal-dominant polycystic
kidney disease. Intern Med J. 46:883–892. 2016. View Article : Google Scholar
|
|
86
|
Iliuta IA, Kitchlu A and Pei Y:
Methodological issues in clinical trials of polycystic kidney
disease: A focused review. J Nephrol. 30:363–371. 2017. View Article : Google Scholar
|
|
87
|
Yaghoubian A, de Virgilio C, White RA and
Sarkisyan G: Increased incidence of renal cysts in patients with
abdominal aortic aneurysms: A common pathogenesis? Ann Vasc Surg.
20:787–791. 2006. View Article : Google Scholar
|
|
88
|
Kolatsi-Joannou M, Bingham C, Ellard S,
Bulman MP, Allen LI, Hattersley AT and Woolf AS: Hepatocyte nuclear
factor-1beta: A new kindred with renal cysts and diabetes and gene
expression in normal human development. J Am Soc Nephrol.
12:2175–2180. 2001.
|
|
89
|
Ta MH, Schwensen KG, Liuwantara D, Huso
DL, Watnick T and Rangan GK: Constitutive renal Rel/nuclear
factor-κB expression in lewis polycystic kidney disease rats. World
J Nephrol. 5:339–357. 2016. View Article : Google Scholar
|
|
90
|
Bergmann C, von Bothmer J, Ortiz Bruchle
N, Venghaus A, Frank V, Fehrenbach H, Hampel T, Pape L, Buske A,
Jonsson J, et al: Mutations in multiple PKD genes may explain early
and severe polycystic kidney disease. J Am Soc Nephrol.
22:2047–2056. 2011. View Article : Google Scholar
|
|
91
|
Hian CK, Lee CL and Thomas W:
Renin-angiotensin-aldosterone system antagonism and polycystic
kidney disease progression. Nephron. 134:59–63. 2016. View Article : Google Scholar
|
|
92
|
Chapman AB: Autosomal dominant polycystic
kidney disease: Time for a change? J Am Soc Nephrol. 18:1399–1407.
2007. View Article : Google Scholar
|
|
93
|
Zhang W, Tan AY, Blumenfeld J, Liu G,
Michaeel A, Zhang T, Robinson BD, Salvatore SP, Kapur S, Donahue S,
et al: Papillary renal cell carcinoma with a somatic mutation in
MET in a patient with autosomal dominant polycystic kidney disease.
Cancer Genet. 209:11–20. 2016. View Article : Google Scholar
|
|
94
|
Gansevoort RT, Arici M, Benzing T, Birn H,
Capasso G, Covic A, Devuyst O, Drechsler C, Eckardt KU, Emma F, et
al: Recommendations for the use of tolvaptan in autosomal dominant
polycystic kidney disease: A position statement on behalf of the
ERA-EDTA working groups on inherited kidney disorders and european
renal best practice. Nephrol Dial Transplant. 31:337–348. 2016.
View Article : Google Scholar
|
|
95
|
Riwanto M, Kapoor S, Rodriguez D,
Edenhofer I, Segerer S and Wuthrich RP: Inhibition of aerobic
glycolysis attenuates disease progression in polycystic kidney
disease. PLoS One. 11:e01466542016. View Article : Google Scholar
|
|
96
|
Ta MH, Schwensen KG, Foster S, Korgaonkar
M, Ozimek-Kulik JE, Phillips JK, Peduto A and Rangan GK: Effects of
TORC1 inhibition during the early and established phases of
polycystic kidney disease. PLoS One. 11:e01641932016. View Article : Google Scholar
|
|
97
|
Couillard M, Guillaume R, Tanji N, D'Agati
V and Trudel M: c-myc-induced apoptosis in polycystic kidney
disease is independent of FasL/Fas interaction. Cancer Res.
62:2210–2214. 2002.
|
|
98
|
Raina R, Lou L, Berger B, Vogt B, Sao-Mai
Do A, Cunningham R, Vasavada P, Herrmann K, Dell K and Simonson M:
Relationship of urinary endothelin-1 with estimated glomerular
filtration rate in autosomal dominant polycystic kidney disease: A
pilot cross-sectional analysis. BMC Nephrol. 17:222016. View Article : Google Scholar
|
|
99
|
Kocer D, Karakukcu C, Ozturk F, Eroglu E
and Kocyigit I: Evaluation of fibrosis markers: Apelin and
transforming growth factor-β1 in autosomal dominant polycystic
kidney disease patients. Ther Apher Dial. 20:517–522. 2016.
View Article : Google Scholar
|
|
100
|
Martins DP, Souza MA, Baitello ME,
Nogueira V, Oliveira CI, Pinhel MA, Caldas HC, Filho MA and Souza
DR: Vascular endothelial growth factor as an angiogenesis biomarker
for the progression of autosomal dominant polycystic kidney
disease. Genet Mol Res. 15:2016. View Article : Google Scholar
|
|
101
|
Peda JD, Salah SM, Wallace DP, Fields PE,
Grantham CJ, Fields TA and Swenson-Fields KI: Autocrine IL-10
activation of the STAT3 pathway is required for pathological
macrophage differentiation in polycystic kidney disease. Dis Model
Mech. 9:1051–1061. 2016. View Article : Google Scholar
|
|
102
|
de Melo AS, Dias SV, Cavalli Rde C,
Cardoso VC, Bettiol H, Barbieri MA, Ferriani RA and Vieira CS:
Pathogenesis of polycystic ovary syndrome: Multifactorial
assessment from the foetal stage to menopause. Reproduction.
150:R11–R24. 2015. View Article : Google Scholar
|
|
103
|
Borie R, Kannengiesser C, Dupin C, Debray
MP, Cazes A and Crestani B: Impact of genetic factors on fibrosing
interstitial lung diseases. Incidence and clinical presentation in
adults. Presse Med. 49:1040242020. View Article : Google Scholar
|
|
104
|
Ballew BJ and Savage SA: Updates on the
biology and management of dyskeratosis congenita and related
telomere biology disorders. Expert Rev Hematol. 6:327–337. 2013.
View Article : Google Scholar
|
|
105
|
Li H, Zhang Y, Dan J, Zhou R, Li C, Li R,
Wu X, Singh SK, Chang JT, Yang J and Luo Y: p53 mutation regulates
PKD genes and results in co-occurrence of PKD and tumorigenesis.
Cancer Biol Med. 16:79–102. 2019. View Article : Google Scholar
|
|
106
|
Duffy MJ, Synnott NC, O'Grady S and Crown
J: Targeting p53 for the treatment of cancer. Semin Cancer Biol.
Jul 30–2020.(Epub ahead of print). View Article : Google Scholar
|
|
107
|
Sugarman ET, Zhang G and Shay JW: In
perspective: An update on telomere targeting in cancer. Mol
Carcinog. 58:1581–1588. 2019. View Article : Google Scholar
|
